



AerovectRx Names Tom Callaway as CEO

Atlanta, GA, June 2, 2009 - Thomas H. Callaway, M.D., MBA, has been named Chief Executive Officer of AerovectRx Corporation, an Atlanta-based inhaled, aerosol drug-delivery company.

Prior to joining AerovectRx, Tom was founder and President of Life Science Partner, an executive search firm focused on recruiting scientific and managerial leaders for the life sciences industry. He was also a founding partner of Georgia Venture Partners, established in 2004 to make seed and early-stage investments in life sciences enterprises related to Georgia. He is a former partner with Fuqua Ventures (a life science and technology venture capital fund) and two leading recruiting firms Russell Reynolds and Korn/Ferry International.

Before moving to Atlanta, Dr. Callaway held the position of Director, Commercial Development for SyStemix, responsible for business development and marketing for the firm's proprietary stem cell technology. He began his biotechnology career at Roche Diagnostics and Roche Molecular Systems. During his tenure at Roche, he developed and executed a global marketing plan for polymerase chain reaction (PCR) diagnostics technology, a Noble-prize winning solution for sleuthing out specific sequences of DNA and commercializing the tools to map the human genome.

"With the appointment of Tom as CEO, AerovectRx has secured a successful, experienced and highly capable executive," said P. Kathleen Lovell, Board Chairman.

Dr. Callaway added, "Inhaled drug delivery is emerging as one of the most lucrative segments in the pharma industry and I am very excited to become a part of the AerovectRx team as we accelerate into this opportunity."

Dr. Callaway earned a medical degree from Vanderbilt University School of Medicine. He holds an MBA and undergraduate degree from Duke University.

Dr. Callaway was recently awarded the 2009 Georgia Bio Industry Growth Award as recognition for his years of service and extraordinary contributions to Georgia's life sciences community and as a mentor to industry entrepreneurs.

Tom is an active member of the Southeast investment community, serving on the board of Atlanta Venture Forum, Southeast Bio, and the Bio 2009 Executive Committee. He is a member of the corporate board of Aruna Biomedical, Aterain, and Neurop.

Callaway, 49, has served since December 2008 as AerovectRx interim CEO.

[About AerovectRx](#) - Founded in 2005, AerovectRx is an inhaled aerosol drug delivery company and the exclusive licensee of patented Centers for Disease Control technology originally developed for aerosolization of vaccines. AeroCELL™, AerovectRx's commercial adaptation of the CDC technology, is a small, highly portable, simply operated, hand-held device, utilizing vibrating mesh technology that efficiently and reliably delivers small molecule drugs and complex biologics including vaccines, to the respiratory tract.

Media Contact:
Sara Gatlin
sgatlin@aerovectrx.com
404-920-2052